Otomycosis: prevalence, clinical symptoms, therapeutic procedure.
Local lesions observed in otitis, create favourable conditions for the growth of fungi and development of mycoses both in the external and middle ear, as well as in post-operative cavities, especially in cases of open-type surgery. The objective of this study was: (1) to determine the prevalence of mycotic infections in inflammatory conditions of the ear; (2) to evaluate the relationship between the presence of fungi and clinical symptoms of inflammation; and (3) to construct a model of therapeutic procedure. The study concerned 345 individuals, including 295 patients (381 ears) who presented with symptoms of otitis. The mycological examinations revealed presence of fungi in 30.4% cases (116 ears). Positive culture results were obtained predominantly in patients with post-operative suppuration (52.8%). Otomycosis was more often associated with fungi of the genus Candida (3/5) than with fungi of the genus Aspergillus (2/5). The analysis of symptoms in otomycoses showed that in bacteria-induced otitis, pruritus, discharge, post-operative defective hearing and headaches are most common; the analysis of signs showed that reddened epidermis and lining of the tympanic cavity are statistically more frequent. The therapeutic protocol adopted in otomycoses yields good results: 89%--complete cure.
Kurnatowski
P
P
Centre for Treatment of Parasitic Diseases and Mycoses, Medical University of Lódź, Poland. pkurna@katedra.dofa.am.lodzpl
Filipiak
A
A
D000935:Antifungal Agents / Q000627:therapeutic use*; D001230:Aspergillus / Q000302:isolation & purification; D002175:Candida / Q000302:isolation & purification; D015725:Fluconazole / Q000627:therapeutic use; D005658:Fungi / Q000302:isolation & purification*; D006261:Headache / Q000473:pathology; D006311:Hearing Disorders / Q000473:pathology; D006801:Humans; D009181:Mycoses / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D010866:Natamycin / Q000627:therapeutic use; D010031:Otitis / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D011183:Postoperative Complications / Q000382:microbiology; D011537:Pruritus / Q000473:pathology; D013492:Suppuration / Q000382:microbiology; D016896:Treatment Outcome
D000935:Antifungal Agents; D010866:Natamycin; D015725:Fluconazole